Beta Thalassemia Transfusion Dependent — Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
Citation(s)
Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* < 20 Msec